Stocklytics Platform
Array BioPharma
ARRY57
$6.03arrow_drop_down0.49%-$0.02
ARRY57

$6.03

arrow_drop_down0.49%

Analyst Forecast

no data available for Analyst Forecast

There's no data available for Analyst Forecast

Period: -

• Predicted: -

Analyst Ratings

no data available for Analyst Ratings

There's no data available for Analyst Ratings

Last updated: -

• Total: -

Array BioPharma (ARRY) Stocklytics Forecast

Array BioPharma Inc (ARRY) has been showing promising potential in the biopharmaceutical industry, and its stock price has attracted the attention of investors. Many experts and analysts have weighed in on the future outlook for ARRY, providing stock price predictions and forecasts based on various factors. These predictions can offer valuable insights for investors looking to make informed decisions.
Based on AI price prediction models and machine learning algorithms, the forecast for ARRY looks positive. These models analyze historical data, market trends, and other relevant factors to generate predictions. While these predictions are not guaranteed, they can help investors make more informed choices. The forecast for ARRY stock price in 2023 is expected to be bullish, with potential for growth and positive returns.
add Array BioPharma to watchlist

Keep an eye on Array BioPharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Array BioPharma (ARRY) stock?

Analysts have set a target price of $20.11 for Array BioPharma (ARRY), based on forecasts from 28 analysts. The predicted price range extends from a high of $31 to a low of $12. This represents a potential increase of up to 414.1% and a decrease of 99% from the current price of $6.03. These forecasts are as of 2023 Nov 08.
help

What are the analyst ratings for Array BioPharma (ARRY) stock?

The analyst ratings for Array BioPharma (ARRY) are distributed as follows: 14 analysts recommend buying, 13 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 27 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Array BioPharma .
help

What is the AI price prediction for Array BioPharma (ARRY) stock?

At present, there is no AI or machine-learning-based price prediction available for Array BioPharma (ARRY) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level